Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of QMF149 vs Salmeterol/Fluticasone in COPD
NCT01636076Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2012
- Primary completion
- Sep 2013
- Modality
- Orthosteric Ligands
- Countries
- 18
01
Overview
A Phase 2 trial of indacaterol, mometasone in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Nov 2012; status: completed.
02
Drugs
indacaterolmometasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01636076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01636076.